<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05032027</url>
  </required_header>
  <id_info>
    <org_study_id>JCL2021-1</org_study_id>
    <nct_id>NCT05032027</nct_id>
  </id_info>
  <brief_title>Oral Probiotics on Radiation Enteritis Stage Ⅱ Induced by Pelvic Concurrent Chemoradiotherapy</brief_title>
  <acronym>probiotics</acronym>
  <official_title>A Randomized Controlled Clinical Study of Oral Probiotics on Radiation Enteritis Stage Ⅱ Induced by Pelvic Concurrent Chemoradiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangxi Provincial Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangxi Provincial Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effect of Probiotics on Raditon Enteritis in Pelvic Tumor Patients Receiving Radiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiation-induced enteritis is an common and severe side effect of the patients undergoing&#xD;
      pelvic radiotherapy. It can lead to dose-limiting and debilitating treatment effect. There is&#xD;
      no guideline on an acknowledged intervention that significantly reduces its severity. In&#xD;
      previous study, we have abserved that a probiotic combination significantly enhances the&#xD;
      immune response of patients and reduces the severity of oral mucositis through modification&#xD;
      of gut microbiota. In this stuyd we plan to designe a randomized trial of Probiotics&#xD;
      probiotics in patients with pelvic carcinoma.The aim of this study is to determine if&#xD;
      regulating intestinal tract flora will reduce the severity of radiation-induced mucositis in&#xD;
      patients receiving pelvic radiotherapy. The effect of this intervention on a patient's&#xD;
      general well-being was also investigated. The primary end-point of the study was the&#xD;
      incidence of grade 3 enteritis. In 2021, 40 patients are estimated to be recruited into the&#xD;
      study in Jiangxi Cancer Hospitals, China. 20 patients were randomized to receive Probiotics&#xD;
      or placebo during chemoradiotherapy respectively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 27, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 27, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The random assignment of patients was performed by Nanchang Medical University with a computer-generated random number code. Patients were randomly distributed in a 1:1 ratio to receive probiotics or a placebo (the block size was known only to the statistician). The drug was distributed and packaged in accordance with random numbers, and the documents stating the parameters, such as the blinding codes for the seeds of the random numbers, the block length, and the random numbers, were sealed in envelopes</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>grade 3 entiritis</measure>
    <time_frame>one month</time_frame>
    <description>Diarrhea more than seven times a day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>one month</time_frame>
    <description>Adverse drug events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immune index</measure>
    <time_frame>one month</time_frame>
    <description>immune globulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in intestinal flora</measure>
    <time_frame>one month</time_frame>
    <description>Dung sequencing</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pelvic Cancer, Enteritis, Probiotics,Chemoradiotherapy</condition>
  <arm_group>
    <arm_group_label>Probiotic group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Probiotic( recieving Probiotic at the first day of chemoradiotherapy daily)with radiotherapy and Chemotherapy Intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>placebo( one times a day)with radiotherapy and Chemotherapy Intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>healthy control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>probiotics</intervention_name>
    <description>recieving probiotics at the first day of chemoradiotherapy daily</description>
    <arm_group_label>Probiotic group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Karnofsky score ≥80 pelvic tumor patients receiving chemoradiotherapy in our Cancer&#xD;
             Center&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  any immune system disease under high risk to antimicrobial agents such as&#xD;
             Diabetes,infection disease or drug allergy to Probiotics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunling Jiang, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>radiation department of Jiangxi cancer hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chunling Jiang, MD,PHD</last_name>
    <phone>+8613979109200</phone>
    <email>jclil2002@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaodan Chen, PHD</last_name>
    <phone>+8615270865798</phone>
    <email>chenxiaodan@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jiangxi Cancer Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaodan Chen, MD</last_name>
      <phone>+8615270865798</phone>
      <email>chenxiaodan@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>September 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pelvic Neoplasms</mesh_term>
    <mesh_term>Enteritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

